Figure 1.

Benchmarks for molecular response rates with imatinib. 12-year incidences are 91% for MR2 (equivalent to CCR), 89% for MR3 (MMR), 82% for MR4, 72% for MR4.5 and 54% for MR5. Data updated from CML study IV. (M Pfirrmann, update of Ref. 55).